Stay updated with breaking news from Pascal Touchon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) was the target of a large decrease in short interest in May. As of May 31st, there was short interest totalling 12,620,000 shares, a decrease of 11.0% from the May 15th total of 14,180,000 shares. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is […]
Josh Arnold Investment Consultant LLC raised its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 73.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 52,000 shares of the biotechnology company’s stock after acquiring an additional 22,000 shares during the period. Atara Biotherapeutics makes up about […]
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and... | June 7, 2023
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have received a consensus rating of “Hold” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to […]
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have earned a consensus recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the […]